There have been limited multi-participant studies evaluating response to BRAF/MEK inhibitor therapy in patients with recurrent BRAF V600E-positive PCP, although multiple case studies in adults showed response to a second, and in one study even a third, course of the same targeted therapy (66–68). Here, BRAF is linked to pneumocystosis.